Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 20.37M 14.59M 12.6M 11.61M 10.87M 1.39B 20.69M 137M 53.46M 675M 54.76M 53.59M 2.34B P/E Ratio 2024
-5.24x
P/E Ratio 2025 -7.5x
Enterprise Value 20.14M 14.43M 12.46M 11.48M 10.75M 1.37B 20.45M 136M 52.86M 667M 54.14M 52.99M 2.31B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
91.6%
Yield 2024 *
-
Yield 2025 -
1 month-81.33%
3 months-87.50%
6 months-86.00%
Current year-89.24%
1 month 0.01
Extreme 0.014
0.08
Current year 0.01
Extreme 0.014
0.13
1 year 0
Extreme 0.0033
0.24
3 years 0
Extreme 0.0005
0.25
5 years 0
Extreme 0.0005
0.25
10 years 0
Extreme 0.0005
0.25
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member 62 -
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 14.55M
-2.41%+0.14%+39.53%+154.43% 1,035B
+1.07%+3.48%+53.75%+50.64% 574B
+1.32%+0.22%+18.35%+65.35% 397B
+0.58%+0.77%+21.19%+15.95% 324B
-0.85%-0.68%+23.44%+14.94% 281B
+0.44%+5.39%+25.86%+35.39% 278B
+1.66%+1.20%-44.41%-47.37% 193B
+0.32%+1.61%+19.48%+63.42% 191B
-0.22%-2.76%+12.08%+61.30% 156B
Average +0.20%+1.68%+18.81%+46.00% 381.1B
Weighted average by Cap. -0.30%+2.39%+28.20%+71.91%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.34
Net income -1.71M -1.22M -1.06M -973K -911K -116M -1.73M -11.49M -4.48M -56.57M -4.59M -4.49M -196M -3.53M -2.53M -2.19M -2.01M -1.88M -240M -3.59M -23.78M -9.27M -117M -9.5M -9.29M -405M
Net Debt -113K -80.67K -69.68K -64.21K -60.1K -7.67M -114K -758K -296K -3.73M -303K -296K -12.92M -231K -165K -143K -131K -123K -15.7M -234K -1.55M -605K -7.64M -620K -607K -26.45M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume

Annual profits - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!